- Home
- MIRA
as 10-28-2025 4:00pm EST
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 27.7M | IPO Year: | 2023 |
| Target Price: | N/A | AVG Volume (30 days): | 8.8M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.73 - $2.56 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest MIRA Pharmaceuticals Inc. News
MIRA Breaking Stock News: Dive into MIRA Ticker-Specific Updates for Smart Investing
ACCESS Newswire
5 days ago
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
MT Newswires
12 days ago
Sector Update: Health Care Stocks Softer Late Afternoon
MT Newswires
13 days ago
Top Midday Gainers
MT Newswires
13 days ago
Mira Pharmaceuticals Says Oral Mira-55 Outperforms Injected Morphine in New Preclinical Data
ACCESS Newswire
13 days ago
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
ACCESS Newswire
4 months ago
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Benzinga
4 months ago
EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
ACCESS Newswire
4 months ago
MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
Compare MIRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MIRA MIRA Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.